Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
PerkinElmer Inc. (symbol: PKI) is a leading global provider of solutions that enable scientists, researchers, and clinicians to tackle complex challenges in science and healthcare. The company's mission is to innovate for a healthier world through unique solutions that serve the diagnostics, life sciences, food, and applied markets.
PerkinElmer collaborates closely with its customers to deliver earlier and more accurate insights. This is supported by the company's deep market knowledge and technical expertise. With a dedicated workforce of approximately 14,000 employees worldwide, PerkinElmer is committed to improving the quality of life, creating healthier families, and sustaining the wellbeing and longevity of people globally.
In 2020, PerkinElmer reported revenues of approximately $3.8 billion and serves customers in 190 countries. Notably, the company is a component of the S&P 500 index, underscoring its significant market presence and financial stability.
Recent Achievements and Current Projects
- Strategic partnerships with key industry players to enhance diagnostic solutions and life sciences research.
- Continuous investment in innovative technologies and solutions that drive earlier and more accurate healthcare insights.
- Expansion of global reach through new product launches tailored to various market needs.
PerkinElmer's commitment to innovation and collaboration makes it a crucial player in the healthcare and scientific research sectors. By leveraging its extensive expertise and comprehensive solutions, the company strives to address the most pressing challenges faced by its customers.
PerkinElmer, Inc. (NYSE: PKI) has declared a quarterly dividend of $0.07 per share, scheduled for payment on August 11, 2023. Shareholders on record as of July 21, 2023 will be eligible to receive this payment. In 2022, the company reported revenues of approximately $3.3 billion and serves customers globally across 190 countries. As a component of the S&P 500 index, PerkinElmer remains a significant player in the life sciences and diagnostics sector, focusing on providing comprehensive solutions for disease diagnosis and drug discovery. The company is set to undergo a name change in the second quarter of 2023, reinforcing its commitment to innovation and market leadership.
PerkinElmer Inc. (NYSE: PKI) will release its first quarter 2023 financial results on May 11, 2023, before market open. A conference call hosted by CEO Prahlad Singh and CFO Max Krakowiak is scheduled for 8:00 a.m. ET on the same day. The company, which is undergoing a name change in the second quarter of 2023, reported approximately $3.3 billion in revenue for 2022 and serves customers across 190 countries. As a significant player in the S&P 500 index, PerkinElmer focuses on providing innovative solutions for disease diagnosis and drug discovery.
Parkland Corporation (TSX: PKI) announced a dividend of $0.34 per share, to be paid on April 14, 2023, for shareholders of record by March 22, 2023. The ex-dividend date is set for March 21, 2023. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes, reflecting Parkland's commitment to returning value to its shareholders. The company's extensive operations span 25 countries, with approximately 4,000 retail locations across Canada, the U.S., and the Caribbean, highlighting its significant market presence and strategic growth initiatives.
PerkinElmer Inc. (NYSE: PKI) has completed the divestiture of its Applied, Food, and Enterprise Services businesses to New Mountain Capital. This strategic move allows PerkinElmer to focus on its new Life Sciences and Diagnostics company, which aims to drive scientific innovation and improve global health outcomes. The company plans to unveil a new name and ticker symbol in Q2 2023, pending shareholder approval. With approximately $3.3 billion in revenue in 2022 and operations in 190 countries, the restructured organization is poised for growth and will maintain strong commitments to service and corporate citizenship.
PerkinElmer (NYSE: PKI) announced its participation in the virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum scheduled for March 21, 2023, at 2:15 p.m. ET. Senior executives Steve Willoughby and Alan Fletcher will discuss the company's strategic priorities. Registration for the event is available here. A live audio webcast will be accessible on the company’s website, with a replay available for 30 days following the event.
PerkinElmer, a leader in the life sciences sector, has unveiled the EnVision® Nexus™ system, its most advanced multimode plate reader, at SLAS2023. This innovative platform enhances high-throughput screening (HTS) capabilities, significantly supporting drug discovery by allowing researchers to screen millions of samples with improved speed and accuracy. Additionally, PerkinElmer introduced the Zephyr® G3 NGS iQ™ workstation for automating NGS library preparation, further enhancing laboratory efficiency. With its robust portfolio and commitment to advancing scientific research, PerkinElmer aims to drive R&D productivity across various applications.
PerkinElmer (NYSE: PKI) will present at the Cowen 43rd Annual Health Care Conference on March 6 at 9:10 a.m. ET, with CFO Max Krakowiak, and the Barclays Global Healthcare Conference on March 14 at 8:00 a.m. ET, featuring CEO Prahlad Singh. The presentations will provide updates on the company's strategic priorities. Audio webcasts will be available on their website and replays will be accessible for 30 days.
PerkinElmer reported Q4 2022 revenue of $741 million, down from $1,028 million year-over-year, resulting in a 28% decline. The GAAP EPS was $0.85, down from $1.45 a year ago. Full-year revenue also decreased, totaling $3,312 million, compared to $3,828 million in 2021. Operating income dropped significantly, with a GAAP operating profit margin of 22.4% compared to 32.9% the previous year. Despite a challenging year, the company anticipates a 2023 revenue forecast of $2.94 billion with adjusted EPS of $5.05.
FAQ
What is the market cap of PERKINELMER (PKI)?
What does PerkinElmer Inc. do?
What is the mission of PerkinElmer Inc.?
How many employees does PerkinElmer Inc. have?
What was PerkinElmer Inc.'s revenue in 2020?
In how many countries does PerkinElmer Inc. serve customers?
What are some of PerkinElmer Inc.'s recent achievements?
How does PerkinElmer Inc. contribute to healthcare?
Is PerkinElmer Inc. part of any major stock index?
What markets does PerkinElmer Inc. serve?
What is a core focus of PerkinElmer Inc.'s partnerships?
